Green Tea

Green Tea

Common Names

  • Chinese tea
  • Green tea extract
  • Green tea polyphenols
  • Epigallocatechin gallate (EGCG)

For Patients & Caregivers

How It Works

Green tea may help lower cholesterol. Evidence of its cancer preventive effects in humans is not conclusive.

Green tea contains substances called polyphenols, which scientists think contribute to its anticancer activity. Laboratory studies of one polyphenol, catechin epigallocatechin-3-gallate (EGCG), show that it may interfere with several processes involved in cell replication, causing tumor cell death. It also might slow the formation of blood vessels around tumors. Epigallocatechin (ECG), another polyphenol, stops leukemic cells from multiplying in laboratory studies. As an antioxidant, green tea may repair cell damage, but whether it can prevent cancer is uncertain. It is also unknown how it might help protect the heart, but it reduces LDL (“bad”) cholesterol and increases HDL (“good”) cholesterol. Tannins present in green tea generally have antibacterial properties.

Animal studies indicate that oral consumption of green tea extract during fasting can increase the risk of toxicity. It may also interact with various drugs. Human studies are needed.

Purported Uses
  • As an antioxidant
    There is mixed evidence.
  • To prevent and treat cancer
    Although laboratory studies show an anti-cancer effect, a few clinical trials and population surveys show mixed results. A number of studies in China have suggested that high intake may protect against cancers of the colon and stomach.
  • To lower cholesterol and prevent heart disease
    One clinical trial showed that a theaflavin-enriched green tea extract can be used with other dietary approaches to lower a certain type of cholesterol. A few studies suggest possible benefits with drinking green tea on some risk factors for heart disease, but additional studies are needed.
  • To improve mental functioning; for clear thinking
    Caffeinated forms of green tea may stimulate the nervous system.
  • To lower high blood pressure
    Studies show a reduction in the risk of developing high blood pressure.
  • To prevent tooth decay
    Laboratory studies show that green tea may prevent bacteria from attaching to teeth. This use has not been tested in clinical trials.
  • To lose weight
    One human study shows increased expenditure of energy.
  • To increase water loss (as a diuretic)
    No studies support this use.
Patient Warnings
  • Infants should not be fed green tea, as it may interfere with iron metabolism and cause anemia.
Do Not Take If
  • You are pregnant or breastfeeding: Caffeine passes into breast milk and may cause insomnia in the infant.
  • You have a peptic ulcer: Green tea stimulates the production of gastric acid.
  • You are taking adenosine: Caffeine may lessen its effects.
  • You are taking atropine: Green tea may reduce its absorption from the gut and therefore lessen its effects.
  • You are taking codeine: Green tea may reduce its absorption from the gut and therefore lessen its effects.
  • You take warfarin or other blood thinners: In theory, very large amounts on the order of one-half to one gallon per day might lessen the effect of these drugs.
  • You are using bortezomib: Polyphenols can inhibit the effects of this drug.
  • You are taking tamoxifen: Green tea may increase risk of adverse effects of Tamoxifen.
  • You are taking verapamil: Green tea may increase risk of adverse effects of Verapamil.
  • You are taking irinotecan: By inhibiting elimination of irinotecan, EGCG may increase its toxicity.
  • You are taking drugs that are substrates of cytochrome P450 3A4: Green tea may increase the risk of side effects of these drugs.
  • You are taking drugs that are substrates of UGT (Uridine 5’-diphospho-glucuronosyltransferase) enzymes: Green tea may increase the risk of side effects of these drugs.
  • You are taking acetaminophen: Green tea increased liver injury caused by acetaminophen in mice when it was given after acetaminophen.
  • You are taking nadolol: Green tea extract may make it less effective.
  • You are taking palbociclib: Green tea extract may decrease availability of palbociclib, thereby reducing its effectiveness.
  • You are taking Ticagrelor: Green tea polyphenols may inhibit the actions of ticagrelor. Clinical relevance has yet to be determined.
Side Effects
  • Nausea, stomach upset
  • Caffeine can cause insomnia, nervousness, or irritability.

Case Reports

  • Liver toxicity: Several cases have been associated with consumption of green tea.
  • Swelling, itchiness, and darkening of lower lip: In a 40-year-old woman following use of green tea for several years.
  • Blood clots in small blood vessels: In a 38-year-old woman following green tea supplementation for weight loss.
Special Point
  • Green tea can reduce the absorption of iron from the gut. It should be taken either 2 hours before or 4 hours after taking an iron supplement.
Back to top

For Healthcare Professionals

Scientific Name
Camellia sinensis
Clinical Summary

Green tea is a beverage derived from the unfermented leaves of a plant native to Asia. The extract is marketed as a dietary supplement to regulate blood sugar, cholesterol, blood pressure, and for weight loss and cancer prevention. Active constituents include the polyphenol epigallocatechin-3-gallate (EGCG), caffeine, and theanine. Green tea consumption may reduce the risk of hypertension (9) and cardiovascular disease (14), and a theaflavin-enriched extract lowered low-density lipoprotein cholesterol (LDL-C) levels (8). Green tea intake has also been associated with a reduction in self-reported depression (77). Some findings suggest that green tea can enhance glucose tolerance in healthy individuals (11) (12), and reduce fasting blood glucose levels (78). Data from studies on obese (10) (60) and diabetic patients (13) are mixed. But a green tea extract was shown useful, as an adjunct to the standard therapy, to improve arterial stiffness in patients with type-2 diabetes (80).

Topical application of green tea extracts was found effective against external genital and perianal warts (15) (16) (17). One such extract, sinecatechin, is an FDA-approved drug indicated for this use.

Green tea and its active compounds have been studied for their cancer preventive potential. In vitro studies suggest chemopreventive (1) and antiangiogenic (4) effects. Preliminary human studies suggest preventive benefits with green tea extracts among patients with oral premalignant lesions (41), or at high-risk of developing liver (61) or colorectal cancers (64). Another extract produced beneficial biologic responses in patients with chronic lymphocytic leukemia (52).

EGCG, applied topically, can help relieve radiation-induced dermatitis in breast cancer patients (74) (75). In addition, oral EGCG consumption was found to be effective against acute radiation-induced esophagitis in lung cancer patients (76). However, an EGCG-enriched green tea was not useful as maintenance intervention in women with advanced stage ovarian cancer after standard treatment (71), and EGCG supplementation did not reduce likelihood of prostate cancer (63).

In other prostate cancer studies, supplementation with a blend of green tea, pomegranate, broccoli, and curcumin had a protective effect in prostate cancer patients following post-radical treatment (59). Green tea consumption decreased PSA levels in prostate cancer patients prior to prostatectomy (72). However, higher doses of green tea catechins were associated with elevated incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia and/or atypical small acinar proliferation (73).

Data on whether green tea can reduce gastric and esophageal cancer risk are mixed (5) (6) (42). It was also not associated with risk of developing malignant lymphoma or multiple myeloma (65), although data suggest tea intake reduced risk of myelodysplastic syndrome (56). Other data suggest that consumption may actually increase breast cancer risk in postmenopausal women (62). Future studies are needed to resolve this ambiguity and to determine potential beneficial effects of green tea consumption on overall cancer risk (81).

The caffeinated form may cause insomnia and nausea. Use of decaffeinated products may be preferred due to lower incidence of adverse events, but data are inconsistent regarding the relative efficacy of caffeinated versus decaffeinated teas. Animal studies indicate that oral consumption of green tea extract during fasting can increase the risk of toxicity (49). In humans, EGCG intake (200 mg, twice daily for one year) was shown to be safe (70) based on clinical data, whereas a daily dose amounting to 800 mg EGCG was associated with elevated liver enzymes, which was reversible with consumption cessation (67). It is important to distinguish food from concentrated supplements because the dosage varies considerably, and that in turn can either confer benefit or cause harmful effects.

Purported Uses
  • Cancer prevention
  • Cancer treatment
  • Cardiovascular disease
  • Cognitive improvement
  • GI disorders
  • Hypertension
  • Weight loss
Mechanism of Action

Green tea is thought to confer cardiovascular protection by increasing HDL cholesterol and lowering LDL cholesterol and triglycerides (8) (29), as well as by blocking platelet aggregation. The tannins may have antibacterial properties (28) and can produce antidiarrheal effects. The flavonoid constituents may reduce lipoprotein oxidation (30).

Modulation of blood pressure by green tea is thought to be mediated through EGCG. It induces nitric oxide (NO) production via activation of endothelial NO synthase, resulting in vasodilation (27). In healthy subjects, a green tea extract modulated effective brain connectivity during working memory processing (55). EGCG inhibited aggregation of tau protein, thereby reducing toxicity in neuronal model cells (57).

Anticancer activities have been related to polyphenol content, with chemopreventive properties attributed to EGCG via apoptotic induction and tumor antiangiogenesis (20). EGCG may inhibit enzymes involved in cell replication and DNA synthesis by interfering with cell-to-cell adhesion or intracellular communication pathways required for cell division (21). In vitro data indicate that concentrations of 30 mcg/mL EGCG and (-)-epigallocatechin (EGC) inhibit lipoxygenase-dependent arachidonic acid metabolism by 30-75% in normal human colon mucosa and colon cancers (22). Other studies in human colon cancer cell lines suggest that EGCG inhibits topoisomerase I, but not topoisomerase II (23). It also inhibited DNA replication in leukemia cancer cell lines (24), and modulated vascular endothelial growth factor (VEGF) leading to apoptosis in leukemic cells (7).

Administration of green tea inhibits UVB light-induced carcinogenesis; when given before and during carcinogen treatment, it reduced incidence and number of stomach and esophageal tumors in mice (25).

  • Although the U.S. Food and Drug Administration (FDA) includes tea on their list of “Generally Recognized As Safe” substances, pregnant women and women who breastfeed should limit their intake because of caffeine content.
  • Because tea can pass into breast milk, it may cause sleep disorders in nursing infants. Ingestion by infants has been linked to impaired iron metabolism and microcystic anemia.
  • Individuals with peptic ulcers should avoid drinking because it can stimulate the production of gastric acid (29).
Adverse Reactions
  • Green tea is generally considered safe, but because of the caffeine content, excessive consumption can disrupt sleep and cause headaches. A few cases of hepatotoxicity have also been associated with green tea extracts containing high EGCG levels (44) (46) (47) (58).
  • Adverse reactions appear to be dose dependent. Clinical trials reported the following effects:
    — Nausea, abdominal pain, and transaminitis after intake of high dose EGCG (2000 mg orally twice per day) in patients with early stage chronic lymphocytic leukemia (52)
    — Elevation in alanine aminotransferase (ALT) levels, also after consumption of high amounts of EGCG (843 mg daily for one year) by postmenopausal women at risk for breast cancer (68)
    — In another study of EGCG in breast cancer patients, rectal bleeding (with 800mg daily), weight gain, indigestion and insomnia (daily dose of 1200 mg), and liver function abnormality (at 1,600 mg daily) were reported (69).
    However, in a study of men with high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP), EGCG (200 mg, twice daily for one year) was shown to be safe (70).
  • Pruritic swelling and darkening of lower lip following green tea consumption for several years (45) and thrombotic thrombocytopenic purpura after taking a green tea supplement for weight loss (48) have also been reported.
  • When consumed during fasting, green tea extract increased the risk of toxicity in animal studies. Whether it has the same effect in humans is not known (49).
Herb-Drug Interactions
  • Adenosine: The caffeine content may inhibit the hemodynamic effects of adenosine (18).
  • Anticoagulants / Antiplatelets: Theoretically, consumption of large amounts (.5-1 gallon/day) may provide enough vitamin K to antagonize the effects of anticoagulants and antiplatelet agents, though this effect has not been reported in humans (29) (34).
  • Atropine: The tannin content may reduce the absorption of atropine.
  • Iron supplements: The tannin content in may reduce the bioavailability of iron. Green tea should be taken either 2 hours before or 4 hours following iron administration.
  • Codeine: The tannin content may reduce the absorption of codeine (18).
  • Bortezomib: EGCG and other polyphenols can inhibit the therapeutic effect of bortezomib and other boronic acid based proteasome inhibitors (37).
  • Tamoxifen: EGCG was shown to increase the oral bioavailability of tamoxifen, increasing the potential for their interactions (38).
  • Verapamil: The bioavailability of verapamil increased significantly in the presence of EGCG, thought to be due to P-glycoprotein inhibition by EGCG (39).
  • Irinotecan: A study found EGCG to inhibit transport of irinotecan and its metabolite SN-38 into biliary elimination, resulting in their prolonged half-life which can increase toxicity (40).
  • Cytochrome P450 3A4 substrates: Green tea extract inhibits CYP 3A4 enzyme and can affect the intracellular concentration of drugs metabolized by this enzyme (43) (44).
  • UGT (Uridine 5’-diphospho-glucuronosyltransferase) substrates: Green tea modulates UGT enzymes in vitro and can increase the side effects of drugs metabolized by them (51).
  • Acetaminophen: Green tea was shown to increase acetaminophen-induced hepatotoxicity in mice when administered following acetaminophen  (53).
  • Nadolol: Green tea extract inhibits OATP1A2 transporter and can reduce the absorption and plasma concentration of substrate drugs, like nadolol (54).
  • Palbociclib: The bioavailability of Palbociclib decreased following administration of green tea extract in a murine model (79). Clinical relevance has yet to be determined.
  • Ticagrelor: Green tea polyphenols were reported to inhibit the metabolism of ticagrelor, in vitro. Clinical relevance has yet to be determined (82).
Herb Lab Interactions
  • Caffeine in green tea may increase PT / PTT
Dosage (OneMSK Only)
  1. Hsu SD, et al. Chemoprevention of oral cancer by green tea. Gen Dent 2002;50:140-6.
  2. Pisters KM, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001;19:1830-8.
  3. Proniuk S, et al. Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin cancer prevention. J Pharm Sci 2002;91:111-6.
  4. Sartippour MR, et al. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr 2002;132:2307-11.
  5. Sun CL, et al. Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis 2002;23:1497-503.
  6. Nechuta S, Shu XO, Li HL, et al. Prospective cohort study of tea consumption and risk of digestive system cancers: results from the Shanghai Women’s Health Study. Am J Clin Nutr. 2012 Nov;96(5):1056-63. doi: 10.3945/ajcn.111.031419. Epub 2012 Oct 10.
  7. Lee YK, et al. VEGF Receptor Phosphorylation Status and Apoptosis is Modulated by a Green Tea Component, Epigallocatechin-3-gallate (EGCG) in B cell Chronic Lymphocytic Leukemia. Blood 2004;104(3):788-94.
  8. Maron DJ, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med. 2003 Jun 23;163(12):1448-53.
  9. Yang YC, et al.The protective effect of habitual tea consumption on hypertension. Arch Intern Med. 2004 Jul 26;164(14):1534-40.
  10. Brown AL, Lane J, Coverly J, et al. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr. Aug 19 2008:1-9.
  11. Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T, Kimura I. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans.BMC Pharmacol. Aug 26 2004;4:18.
  12. Venables MC, Hulston CJ, Cox HR, Jeukendrup AE. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J Clin Nutr. Mar 2008;87(3):778-784.
  13. Mackenzie T, Leary L, Brooks WB. The effect of an extract of green and black tea on glucose control in adults with type 2 diabetes mellitus: double-blind randomized study. Metabolism. Oct 2007;56(10):1340-1344.
  14. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006;296(10):1255-65.
  15. Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts.J Eur Acad Dermatol Venereol. Nov 2007;21(10):1404-1412.
  16. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.Br J Dermatol. Jun 2008;158(6):1329-1338.
  17. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. Jun 2008;111(6):1371-1379.
  18. Brinker F. Herb Contraindications and Drug Interactions, 3rd ed. Sandy (OR): Eclectic Medical Publications; 2001.
  19. Yang CS, et al. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998;7:351-4.
  20. Tosetti F, Ferrari N, De Flora S. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16:2-14.
  21. Yang CS, et al. Prevention of carcinogenesis by tea polyphenols. Drug Metab Rev 2001;33:237-53.
  22. Hong J, et al. Effects of purified green and black tea polyphenols on cyclooxygenase- and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues. Biochem Pharmacol 2001;62:1175-83.
  23. Berger SJ, et al. Green tea constituent (—)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. Biochem Biophys Res Commun 2001;288:101-5.
  24. Smith DM, et al. Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis. Int J Mol Med 2001;7:645-52.
  25. Huang MT, et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res 1997;57:2623-9.
  26. Yang CS, et al. Human salivary tea catechin levels and catechin esterase activities: implications in human cancer prevention studies. Cancer Epidemiol Biomarkers Prev 1999;8:83-9.
  27. Lorenz M, Wessler S, Follmann E, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. Feb 13 2004;279(7):6190-6195.
  28. Hamilton-Miller JM. Anti-cariogenic properties of tea (Camellia sinensis). J Med Microbiol 2001;50:299-302.
  29. LaValle JB, et al. IN: Natural Therapeutics Pocket Guide 2000-2001;452-4.
  30. Dulloo AG, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999;70:1040-5.
  31. van het Hof KH, et al. Bioavailability of catechins from tea: the effect of milk. Eur J Clin Nutr 1998;52:356-9.
  32. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992;21:334-50.
  33. He YH, Kies C. Green and black tea consumption by humans: impact on polyphenol concentrations in feces, blood, and urine. Plant Foods Hum Nutr 1994;46:221-9.
  34. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999;33:426-8.
  35. Tsubono Y, et al. Green tea and the risk of gastric cancer in Japan. N Engl J Med 2001;344:632-6
  36. Li Q, Kakizaki M, Kuriyama S, et al. Green tea consumption and lung cancer risk: the Ohsaki study. Br J Cancer 2008 Oct 7;99(7):1179-84.
  37. Goldin EB, Lam P, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid based proteasome inhibitors. Blood 2009 Jun 4;113(23):5927-37.
  38. Shin SC, Choi JS. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs. 2009 Aug;20(7):584-8.
  39. Chung JH, Choi DH, Choi JS. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos. 2009 Mar;30(2):90-3.
  40. Lin LC, Wang MN, Tsai TH. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact. 2008 Aug 11;174(3):177-82.
  41. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila Pa). 2009 Nov;2(11):931-41.
  42. Myung SK, Bae WK, Oh SM, et al. Green tea consumption and risk of stomach cancer: a meta-analysis of epidemiologic studies. Int J Cancer. 2009 Feb 1;124(3):670-7.
  43. Wanwimolruk S, Wong K, Wanwimolruk P. Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4. Drug Metabol Drug Interact. 2009;24(1):17-35.
  44. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 2009 Apr;65(4):331-41.
  45. Lee JI, Cho BK, Ock SM, Park HJ. Pigmented contact cheilitis: from green tea? Contact Dermatitis. 2010 Jan;62(1):60-1.
  46. Vanstraelen S, Rahier J, Geubel AP. Jaundice as a misadventure of a green tea (camellia sinensis) lover : a case report. Acta Gastroenterol Belg. 2008 Oct-Dec;71(4):409-12.
  47. Verhelst X, Burvenich P, Van Sassenbroeck D, Gabriel C, Lootens M, Baert D. Acute hepatitis after treatment for hair loss with oral green tea extracts (Camellia Sinensis). Acta Gastroenterol Belg. 2009 Apr-Jun;72(2):262-4.
  48. Liatsos GD, Moulakakis A, Ketikoglou I, Klonari S. Possible green tea-induced thrombotic thrombocytopenic purpura. Am J Health Syst Pharm. 2010 Apr 1;67(7):531-4.
  49. Wu KM. Green Tea Extract Induced Lethal Toxicity in Fasted but Not in Nonfasted Dogs. Int J Toxicol. 2011 Feb;30(1):19-20.
  50. Engdal S, Nilsen OG. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res. 2009 Jul;23(7):906-12.
  51. Mohamed ME, Frye RF. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med. 2011 Mar;77(4):311-21.
  52. Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2012 Jul 3. doi: 10.1002/cncr.27719. [Epub ahead of print]
  53. Salminen WF, Yang X, Shi Q, Greenhaw J, Davis K, Ali AA. Green tea extract can potentiate acetaminophen-induced hepatotoxicity in mice. Food Chem Toxicol. 2012 May;50(5):1439-46.
  54. S Misaka, J Yatabe, F Müller, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther. 2014 Apr;95(4):432-8.
  55. Schmidt A, Hammann F, Wölnerhanssen B, et al. Green tea extract enhances parieto-frontal connectivity during working memory processing. Psychopharmacology (Berl). 2014 Oct;231(19):3879-88.
  56. Liu P, Zhang M, Jin J, Holman CD. Tea consumption reduces the risk of de novo myelodysplastic syndromes. Leuk Res. 2015 Feb;39(2):164-9.
  57. Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 2015 Jan 2;589(1):77-83.
  58. Fernández J, Navascués C, Albines G, Franco L, Pipa M, Rodríguez M. Three cases of liver toxicity with a dietary supplement intended to stop hair loss. Rev Esp Enferm Dig.2014 Dec;106(8):552-5.
  59. Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):180-6.
  60. Dostal AM, Arikawa A, Espejo L, et al. Long-term supplementation of green tea extract does not modify adiposity or bone mineral density in a randomized trial of overweight and obese postmenopausal women. J Nutr. Dec 23 2015.
  61. Xue KS, Tang L, Cai Q, et al. Mitigation of fumonisin biomarkers by green tea polyphenols in a high-risk population of hepatocellular carcinoma. Sci Rep. 2015;5:17545.
  62. Li M, Tse LA, Chan WC, Kwok CH, et al. Evaluation of breast cancer risk associated with tea consumption by menopausal and estrogen receptor status among Chinese women in Hong Kong.Cancer Epidemiol. 2015 Dec 8;40:73-78.
  63. Kumar NB, Pow-Sang J, Egan KM, et al. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila).2015 Oct;8(10):879-87.
  64. Shin CM, Lee DH, Seo AY, et al. Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial. Clin Nutr. 2017 Jan 29. pii: S0261-5614(17)30038-9.
  65. Ugai T, Matsuo K, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Kanda Y, Tsugane S; Japan Public Health Center-based Prospective Study Group. Coffee and Green Tea Consumption and Subsequent Risk of Malignant Lymphoma and Multiple Myeloma in Japan: The Japan Public Health Center-based Prospective Study. Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1352-1356.
  66. Dekant W, Fujii K, Shibata E, Morita O, Shimotoyodome A. Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements. Toxicol Lett. 2017 Aug 5;277:104-108.
  67. Yu Z, Samavat H, Dostal A, et al. Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States. Cancer Prev Res (Phila). 2017 Aug 1. pii: canprevres.0160.2017. doi: 10.1158/1940-6207.CAPR-17-0160. [Epub ahead of print]
  68. Dostal AM, Samavat H, Bedell S, et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. Food Chem Toxicol. 2015 Sep;83:26-35.
  69. Crew KD, Ho KA, Brown P, et al. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet. 2015 Jun;28(3):272-82.
  70. Kumar NB, Pow-Sang J, Spiess PE, et al. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct 25;7(43):70794-70802.
  71. Trudel D, Labbé DP, Araya-Farias M, et al. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013 Nov;131(2):357-61.
  72. Henning SM, Wang P, Said JW, et al. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015 Apr 1;75(5):550-9.
  73. Gontero P, Marra G, Soria F, et al. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or “chemopromotion”? Prostate. 2015 Aug 1;75(11):1177-86.
  74. Zhu W, Jia L, Chen G, et al. Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy. Oncotarget. 2016 Jul 26;7(30):48607-48613.
  75. Zhao H, Zhu W, Jia L, et al. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy. Br J Radiol. 2016;89(1058):20150665.
  76. Zhao H, Xie P, Li X, et al. A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer. Radiother Oncol. 2015 Mar;114(3):351-6.
  77. Kim J, Kim J. Green Tea, Coffee, and Caffeine Consumption Are Inversely Associated with Self-Report Lifetime Depression in the Korean Population. Nutrients. 2018 Sep 1;10(9). pii: E1201.
  78. Kondo Y, Goto A, Noma H, Iso H, Hayashi K, Noda M. Effects of Coffee and Tea Consumption on Glucose Metabolism: A Systematic Review and Network Meta-Analysis. Nutrients. 2018 Dec 27;11(1). pii: E48.
  79. Paul D, Surendran S, Chandrakala P, Satheeshkumar N. An assessment of the impact of green tea extract on palbociclib pharmacokinetics using a validated UHPLC-QTOF-MS method. Biomed Chromatogr. 2018 Dec 13:e4469.
  80. Quezada-Fernández P, Trujillo-Quiros J, Pascoe-González S, et al. Effect of green tea extract on arterial stiffness, lipid profile and sRAGE in patients with type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled trial. Int J Food Sci Nutr. 2019 Dec;70(8):977-985.
  81. Filippini T, Malavolti M, Borrelli F, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev. 2020 Mar 2;3:CD005004.
  82. Wang ZT, Xue Y, Sun H, et al. Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. J Food Sci. 2020 Apr;85(4):1285-1291.
Back to top
Back to top
Email your questions and comments to

Last Updated